{module_contentholder name="header-part-1"}
    <title>Novogen - Management</title>
{module_contentholder name="header-part-2"}
<meta name="description" content="Bio-pharmaceutical company using breakthrough technology to create the CS-6 family of drugs to selectively kill cancer stem cells, without side effects.">
{module_contentholder name="header-part-3"}
<!-------------------------------------------------------------->

<div class="about-top uk-vertical-align">
  <div class="uk-vertical-align-middle">
    <h1>The Management Team</h1>
  </div>
</div>
<div class="team-wrap">
  <div class="team-member">
    <div class="team"><img src="img/gkLg.png"></div>
    <div class="team-topline-wrap">
      <div class="team-topline"></div>
      <div class="team-heading">
        <h2 class="uk-margin-bottom-remove">Dr Graham Kelly</h2>
        <h4 class="uk-margin-top-remove">
          BSc, BVSc, PhD
          <br>Executive Director &amp; CEO
        </h4>
      </div>
    </div>
    <div class="team-box uk-vertical-align uk-text-center uk-visible-large"><a href="https://twitter.com/Novogen" target="_blank"><i class="uk-icon-large uk-icon-twitter uk-vertical-align-middle"></i></a></div>

    <div class="team-bottom-line"></div>
  </div>
  <div class="team-text">
    <p>
      Dr Kelly is the founder and previous CEO and Chairman of ASX-listed and NASDAQ-listed companies, Novogen Ltd and Marshall Edwards Inc. Both companies were built on the concept of benzopyran drug technology that emanated from his 25 years in cancer research in the Faculty of Medicine at The University of Sydney.
      <!--        <p>Dr Kelly personally oversaw the design and implementation of thirty-three Phase I and II clinical trials, and a multi-national Phase III trial in conjunction with the US FDA.<br>Dr Kelly has been awarded an Adjunct Professorship by the University of Sydney.-->
    </p>
  </div>
  <div class="double-lines"></div>

  <div class="profile-right">
    <div class="profile-box uk-vertical-align uk-text-center uk-hidden-small"><a href="https://twitter.com/Novogen" target="_blank"><i class="uk-icon-large uk-icon-twitter uk-vertical-align-middle"></i></a>
    </div>
    <!--      <div class="boardmember-topline"></div>-->
    <div class="profile-heading">
      <h2 class="uk-margin-bottom-remove">Dr Andrew Heaton </h2>
      <h4 class="uk-margin-top-remove">
        BSc, PhD
        <br>Vice-President, Drug Discovery
      </h4>
    </div>
    <div class="profile-image-container"><img class="profile-img uk-align-right" src="img/ah.png"
                                              ></div>

  </div>
  <div class="team-text">
    <p>
      Dr Heaton has extensive drug discovery background. He studied the complex interactions of signalling molecules associated with the mass spawning phenomena on the Great Barrier Reef. Following completion of his Ph.D studies he completed post-doctoral research discovering molecules with unique biological activity from marine environment.
    <p>Dr Heaton first joined Novogen in 1998 as General Manager of the drug discovery program; progressing 4 compounds to clinical trials. He was responsible for the design and execution of the Novogen drug.
    </p>
  </div>
  <div class="double-lines"></div>

  <!--      </div>-->

  <div class="team-member">
    <div class="team-img-wrap"><img src="img/db.png"></div>
    <div class="team-topline-wrap">
      <div class="team-topline"></div>
      <div class="team-heading">
        <h2 class="uk-margin-bottom-remove">Dr David Brown </h2>
        <h4 class="uk-margin-top-remove">
          Dip Tech Mgmt, B App Sc, PhD
          <br>Chief Scientific Officer
        </h4>
      </div>
    </div>
    <div class="team-box uk-vertical-align uk-text-center uk-visible-large"><a href="https://twitter.com/Novogen" target="_blank"><i class="uk-icon-large uk-icon-twitter uk-vertical-align-middle"></i></a></div>

    <div class="team-bottom-line"></div>
    <div class="team-text">
      <p>
        Dr. David Brown joined Novogen in 2000 and championed the pre-clinical and translational development of Phenoxodiol, Triphendiol, ME-128, ME-143 and ME-344. In 2010, Dr Brown left Novogen and worked as a Medical Advisor for Janssen as part of the Regional Immunology group. Dr Brown is a co-founder of Triaxial Pharmaceuticals and as a result of Novogen’s acquisition of Triaxial re-joined Novogen in 2013 as the company’s Group Chief Scientific Officer where he currently oversees all scientific operations both locally and internationally with our commercial and academic partners. Dr Brown currently sits on the  CanTx Board of Directors, Novogen's joint venture company with Yale University.<p>
      Dr Brown has over 20 years’ experience in all non-clinical aspect of drug discovery and development. He holds a PhD from the University of Queensland, and has held several research appointments at the Queensland Institute of Medical Research (University of Queensland) and University of New South Wales. Dr Brown has co-authored 10 patents, several IND applications, and over 30 peer-reviewed scientific articles
      </p>

    </div>
  </div>
  <div class="double-lines"></div>

  <div class="profile-right">
    <div class="profile-box uk-vertical-align uk-text-center uk-hidden-small"><a href="https://twitter.com/Novogen" target="_blank"><i class="uk-icon-large uk-icon-twitter uk-vertical-align-middle"></i></a></div>
    <!--      <div class="boardmember-topline"></div>-->
    <div class="profile-heading">
      <h2 class="uk-margin-bottom-remove">Cristyn Humphreys</h2>
      <h4 class="uk-margin-top-remove">
        BBus(Acc), DipPol, FTI, CA
        <br>Chief Operating Officer (Administration and Finance)
      </h4>
    </div>
    <div class="profile-image-container"><img class="profile-img uk-align-right" src="img/CristynH.png"></div>

  </div>
  <!--            <div class="boardmember-bottomline"></div>-->


  <div class="team-text">
    <p>
      Cristyn has 20 years commercial experience working for private industries including heading up finance, marketing and strategy departments for businesses with a global presence.  Cristyn’s commercial experience is broad including founding a registered charity in Australia and working in the NSW Police Service.  She is a Chartered Accountant and a Fellow of the Tax Institute in Australia.
    </p>
  </div>
  <div class="double-lines"></div>


  <div class="team-member">
    <div class="team-img-wrap"><img src="img/js.png"></div>
    <div class="team-topline-wrap">
      <div class="team-topline"></div>
      <div class="team-heading">
        <h2 class="uk-margin-bottom-remove">Dr Justine Stehn</h2>
        <h4 class="uk-margin-top-remove">
          BSc, PhD
          <br>ATM Program Director
        </h4>
      </div>
    </div>
    <div class="team-box uk-vertical-align uk-text-center uk-visible-large"><a href="https://twitter.com/Novogen" target="_blank"><i class="uk-icon-large uk-icon-twitter uk-vertical-align-middle"></i></a></div>

    <div class="team-bottom-line"></div>
  </div>

  <!--            <div class="boardmember-bottomline"></div>-->


  <div class="team-text">
    <p>
      Dr Stehn joined Novogen in February 2014 and is responsible for the drug development of the ATM program, which was acquired by Novogen in 2013 and Dr Stehn is also the co-inventor.  Dr Stehn has over 20 years research experience in understanding the role of the cell cytoskeleton in disease. After receiving her PhD from the Garvan Institute of Medical Research, Sydney, Justine was awarded a prestigious National Health and Medical Research Council (NHMRC), CJ Martin Fellowship to support her post doctoral positions at Harvard University and the Centre for Cancer Research at the Massachusetts Institute of Technology (MIT), Boston, USA.
    <p>Upon returning to Australia, Justine headed up the Anti-tropomyosin (ATM) drug development program at UNSW Australia. She has been involved in the ATM program since its inception in 2007 and has been instrumental in driving the preclinical development of the ATM compounds for the treatment of cancer.
    </p>
    <p>
      Previous appointments have included leadership roles as Chair of the Division of Research at The Children’s Hospital at Westmead, Chair of the Westmead Research Hub.  Executive, member of the Board, NSW Cancer Institute and Chair, Board of Bio-Link, a company established by the NSW Government to support commercialisation of biomedical intellectual property.
    </p>
  </div>
  <div class="double-lines"></div>

  <div class="profile-right">
    <div class="profile-box uk-vertical-align uk-text-center uk-hidden-small"><a href="https://twitter.com/Novogen" target="_blank"><i class="uk-icon-large uk-icon-twitter uk-vertical-align-middle"></i></a></div>
    <!--      <div class="boardmember-topline"></div>-->
    <div class="profile-heading">
      <h2 class="uk-margin-bottom-remove">Dr Stephen Palmer </h2>
      <h4 class="uk-margin-top-remove">
        BSc, PhD
        <br>Degenerative Diseases Program Director
      </h4>
    </div>
    <div class="profile-image-container"><img class="profile-img uk-align-right" src="img/spalmer.png"
                                              ></div>

  </div>

  <div class="team-text">
    <p>
      Dr Palmer joined Novogen in 2014 and is responsible for running the drug discovery programme centred around stimulating regenerative processes in stem cells and developing novel therapies for degenerative diseases including dementia, muscular dystrophy, lysosomal storage disorders and autoimmune disease.</p><p>Dr Palmer completed his PhD in 1992 at University College London and established a career studying the genetic regulation of embryonic development and inherited disorders. Using genetically modified mice as models of human disease, he has studied normal and abnormal cellular function in several different organ systems.
    </p>
    <p>
      Dr Palmer migrated to Australia on a Wellcome Trust International Travelling Fellowship and worked at the Victor Chang Cardiac Research Institute and the Children’s Medical Research Institute in Sydney. He established a research program on the neurodevelopmental disorder Williams-Beuren syndrome, demonstrating the key role of the GTF2IRD1 protein. He currently holds a conjoint Senior Lectureship at UNSW Australia.
    </p>
  </div>
  <div class="double-lines"></div>

  <div class="team-member">
    <div class="team-img-wrap"><img src="img/kl.png"></div>
    <div class="team-topline-wrap">
      <div class="team-topline"></div>
      <div class="team-heading">
        <h2 class="uk-margin-bottom-remove">Dr Kimberley Lilischkis</h2>
        <h4 class="uk-margin-top-remove">
          BSc, PhD, MBA
          <br>Clinical &amp; Regulatory Affairs Manager
        </h4>
      </div>
    </div>
    <div class="team-box uk-vertical-align uk-text-center uk-visible-large"><a href="https://twitter.com/Novogen" target="_blank"><i class="uk-icon-large uk-icon-twitter uk-vertical-align-middle"></i></a></div>

    <div class="team-bottom-line"></div>
  </div>

  <!--            <div class="boardmember-bottomline"></div>-->


  <div class="team-text">
    <p>
      Kimberley is a Clinical Research and Regulatory Manager with extensive scientific research training. She has clinical trials management knowledge and experience in both the academic research environment and industry. Her scientific research career spans more than 20 years in both clinical and laboratory research areas in Australia and Europe. Kimberley has a focused interest in oncology research and the translation of new findings into improved health outcomes for cancer patients.
    </p>
  </div>
  <div class="double-lines"></div>
</div>
 
   {module_contentholder name="footer"}